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ABSTRACT  
Objective: To examine the presence of Immunoglobulin G type of anti-cardiolipin (ACL), anti-β2GPI  and 
antiphospholipids (aPL) antibody in Iraqi patients with cerebrovascular diseases especially ischemic stroke.  
Methods: Immunoglobulin G type of antiphospholipid antibodies (beta 2-glycoprotein I [B2-GPI]), anti 
phosphatidyl serine, cardiolipin, anti phosphatidyl inositol and anti phosphatidic acid were ivestigated in 67 
patients with ischemic stroke (aged between 20 to 90 years) during an three months period from October 2015 to 
January 2016 in Al-Zahra and  AL-Karama Hospitals, Wassit, Iraq. The clinical, laboratory and demographic 
characteristics of patients with a positive results were registered. 
Results: One man and six women (seven patients, 10.49%) had increased IgG types of antiphospholipid 
antibodies. Increased titers of IgG for anticardiolipin was  observed in eight (11.94%) and seven (10.49%) of 
patients were positive to anti- β2GPI. 
Conclusion: In spite of  the different studies in the Europe, elevated titers of IgG antiphospholipid antibodies 
present in a large number of patients can be resulted from the existence of unidentified triggering agents (poisons 
and infections), that are more common in developing countries in comparison to developed countries. This 
hypothesis still need  to more and more investigation in the future, in our country the morbidity is too high 
because of the repeated wars. 
 
1. Introduction 
Recently, with advances in recognition of complex pathologic  stages of stroke and developing new 
diagnostic laboratory methods, several risk factors like (aPL) antibodies have been recognized in patients with 
stroke (1). In fact, different researches have revealed the correlation of  strokes with anti beta 2-glycoprotein I 
and anticardiolipin (aCL) antibodies. The diagnosis of antiphospholipid antibody syndrome (APS) can be 
assumed when these antibodies are present for more than 8 weeks. Despite these antibodies are cannot be 
detected in a number of patients with clinical investigations of this syndrome, other types of non anticardiolipin 
antibodies (non aCL) for example anti phosphatidyl serine and anti phosphatidyl inositol antibody antibodies can 
be exist in these patients (2-9). Since many years, it has been became obvious that human B2-glycoprotein (anti 
B2-GPI) could differentiate between benign alloimmune aCL and autoimmune aCL (10,11). and could be a more 
specific agent compared to anticardiolipin in explaining the mechanism of thrombosis (12-14). Infact, in many 
cases, it is the only antibody known to be in charge of antiphospholipid syndrome ocuurence (15,16). With 
regard to the role of antiphospholipid antibodies as risk agents for ischemic stroke (particularly frequent stroke), 
the detection of the mentioned antibodies, in patients with strokes are necessary to avoidance of recurrent 
strokes. Meantime, according to the researches in the countries of Europe (17-21). many patients with APS and 
stroke had high titers of Immunoglobulin antibodies in contrast to researches in India (22). which have showed 
incresing levels of antphospholipid antibodies. therefore, in order to identification  the profile of these antibodies 
in developing countries, further studies are mandatory. bearing in mind the poor in sufficient information about 
this field in Iraq, we examined the characteristics of patients with ischemic stroke aged between 20-90 years 
(with unclear causative agents), and the incidence of antiphospholipid antibodies, in Al-Zahra and AL-Karama 
Hospitals of Wassit, Iraq.  
 
2.Methods 
this descriptive study included, 67  patients (aged between 20 t0 90 years) with ischemic stroke 
diagnosed by Computerized Tomography scan were chosen consecutively during an three-months period from 
October 2015 to January 2016 in Al-Zahra and  AL-Karama Hospitals, Wasit, Iraq. After registering the 
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outcomes all patients were clinically investigated, antiphospholipid, anti B2-GPI and anticardiolipin antibody 
test has been done after collection of blood samples by using enzyme linked immunosorbent assay technique, 
using GA4050 (Generic Assays, Diagnostica, Germany, with cardiolipin-, phosphatidyl serine-, phosphatidyl 
inositol-, phosphatidic acid- and B2GPI-coated microplate) for apl, GA4050 (Generic Assays, Diagnostica, 
Germany) for anti-B2GPI and (Aeskulisa3204 Diagnostica, Germany) for aCL diagnostic kits. Serum levels of 
IgG >10 IgG antiphospholipid (GPL) units, for all antibodies were considered positive. The outcomes of other 
laboratory tests including partial thromboplastin time, erythrocyte sedimentation rate and complete blood count 
(to determine abnormal laboratory values accompanied with antiphospholipid antibodies and also autoimmune 
disease AID), previous thrombotic attack, past medical history, demographic characteristics, treatments and 
clinical findings of patients with positive antibody titers,  were registereded. Data were analyzed using SPSS  
Version 20 and minitab Version 14 software. 
 
3.Results 
Seven out of 67  patients with stroke (one male, six females, 10.49%) were positive for aCL, aPL and anti beta 2-
glycoprotein I antibodies. The mean age for patients in this study  was 54.53 ± 17.96 years. According to the 
results, 7(10.49%)  patients were positive to aPL and anti beta 2-glycoprotein I, while  8(11.94%) patients were 
positive to aCL antibody.  Also 1.49% of patients who were negative for aCL-antibody had increased titers 
(positive) of non-aCL antibody (raised titer of IgG of aPL with GA4041 kit). Among studied patients, deep vein 
thrombosis in one and history of previous cerebrovascular diseases was positive in all patients. From 7 patients 
with raised aPL and aCL titers, 7 of them had been admitted to hospital (cardiac and intensive care unit) with the 
diagnosis of transient ischemic attack and infarction. More investigation revealed that these patients had 
thrombotic stroke and embolic infarction was found in these patients. 
 
4.Discussion 
According to the findings of this study, 10.49% of patients were positive for all aPL antibodies. Previous studies 
in this field have reported varying outcomes (from 10-44%) concerning the frequency of these antibodies in 
patients with strokes (1,17,22-24). Arvanitakis et al (25) showed that 11% of patients had high serum aPL  titers 
as compared to 12% in another study accomplished by Jahromi et al (26)  regarding Iranian patients. In 
Saadatnia et al study (27), 13.1% of patients were positive for one or more aPL antibodies especially aCL, and in 
Goor  et al (28) there study showed that the rate of aCL was 17.2%. Also about Beta2glycoprotein I  the positive 
outcomes regarding patients were observed in 10.50% in Shojaei  et al study (29). While Ruiz-Garcia  et al (30) 
found that the rate was very low 6%. These difference may belongs b to the difference in assay methods in 
studied populations or because various normal ranges considered for aPL antibodies. So, further analytic 
researches with larger sample size are suggested to explain the reasons. The above reported  differences can be 
explained through two hypotheses: Considering the higher prevalence of infectious diseases, more frequent 
exposure to toxins in developing countries, lower quality of health care services, poisons or drugs and infections 
can triggering the acute increase of antiphospholipid antibody through a “molecular mimicry” mechanism 
analogous to acute rheumatic fever. aPL antibodies have been detected in drug ingestions, malignancies, and 
infections (31-37). A little unknown geographical or racial differences make the peoples from developing 
countries have more susceptiblity to develop stroke earlier in the phase of acute aPL rising. The mentioned 
hypotheses must be investigated in future studies carefully. 
 
5.Conclusion 
our study shows higher rate of ischemic thrombotic stroke and high levels of IgG aPL antibodies in a large 
number of patients, predominance of female gender, among Iraqi adults patients with stroke. High titers of IgG 
aPL antibodies in a large number of our stroke patients can be caused by the existence of uneplained triggering 
agents (poisons or infections) or geographical differences or undetermined racial, Despite European researches, 
we reported here that some patients were died after few days of diagnosis as aresults to catastrophic 
antiphospholipid syndrome as a result to the exposure to the toxic gases during wars. 
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